scholarly journals 557 DECREASED BONE MINERAL CONTENT (BMC) IN BREAST-FED INFANTS WITHOUT SUPPLEMENTAL VITAMIN D (D): “CATCH UP” MINERALIZATION AT 6 MONTHS AND ONE YEAR; POSSIBLE.EFFECTS ON LENGTH

1981 ◽  
Vol 15 ◽  
pp. 533-533 ◽  
Author(s):  
F R Greer ◽  
J E Searcy ◽  
R S Levin ◽  
J J Steichen ◽  
R C Tsang
1982 ◽  
Vol 100 (6) ◽  
pp. 919-922 ◽  
Author(s):  
Frank R. Greer ◽  
John E. Searcy ◽  
Ronald S. Levin ◽  
Jean J. Steichen ◽  
Paule S. Steichen-Asche ◽  
...  

1981 ◽  
Vol 98 (5) ◽  
pp. 696-701 ◽  
Author(s):  
Frank R. Greer ◽  
John E. Searcy ◽  
Ronald S. Levin ◽  
Jean J. Steichen ◽  
Paule Steichen Asch ◽  
...  

1996 ◽  
Vol 82 (1) ◽  
pp. 65-67 ◽  
Author(s):  
Sandro Barni ◽  
Paolo Lissoni ◽  
Gabriele Tancini ◽  
Antonio Ardizzoia ◽  
Marina Cazzaniga

In this study, the authors have analyzed the possible effects of one-year adjuvant treatment with tamoxifen on bone mineral density in postmenopausal breast cancer women. Bone mineral content was studied by photon absorptiometry (I-125), whereas bone balance was analyzed indirectly by serum PTH, osteocalcin, calcitonin, calcium and alkaline phosphatase levels. Bone mineral content and serum bone-related substances were measured before starting treatment and after one year. Results were analyzed using Student's t test for paired data. No difference was found between the two measurements for bone mineral content, PTH, calcitonin, calcium and alkaline phosphatase levels. Measurements at entry and after one year of treatment showed a statistically significant difference ( P < 0.001) only for osteocalcin. In accordance with other authors, we can conclude that treatment with tamoxifen does not cause an increase in menopausal bone resorption. The finding that osteocalcin levels decreased after one year of therapy with tamoxifen is interesting, but further studies are necessary to clarify the role of such levels in predicting a turnover of bone balance towards osteoblastic activity.


Author(s):  
Corrine Hanson ◽  
Elizabeth Lyden ◽  
Amy Nelson ◽  
Melissa Thoene ◽  
Julie Wagner ◽  
...  

AbstractThe objective of this study was to evaluate the relationship between 25(OH)D, Vitamin D Binding Protein (DBP), and free vitamin D in premature infants.Thirty-two infants <32 weeks’ gestation were randomized to two different levels of vitamin D3 supplementation (400 vs. 800 IU/day). 25(OH)D levels were measured by LC-MS/MS; DBP was measured by validated ELISA. Free vitamin D was calculated using molar ratios of 25(OH)D and DBP. The Wilcoxon signed rank test was used to compare DBP, free D and 25(OH)D levels; Spearman’s correlation coefficients were used to assess correlations.The mean gestational age at birth was 30.5 weeks; mean birth weight was 1405 g. Mean 25(OH)D levels at birth were 17.3 ng/mL; DBP levels were 297 mg/L, and estimated free vitamin D levels were 18.9. There was a statistically significant change in 25(OH)D levels after 8 weeks (24.6 vs. 39.1 ng/mL in the 400 vs. 800 group, respectively, p=0.02). DBP levels from birth to 8 weeks showed a statistically significant decrease (267 vs. 208, p=0.04). Estimated free 25(OH)D concentrations increased over the study period, from 18.9 at birth to 64.7 at 8 weeks of age (p=0.0001). Free vitamin D levels at birth were associated with global DEXA bone mineral content at discharge from the NICU (r=0.58, p=0.05).Supplementation with vitamin D3 increased the free portion of the vitamin D metabolite, providing increased bioavailable substrate. Improved free vitamin D levels may improve measurable outcomes such as bone mineral content and deserve further evaluation.


2012 ◽  
Vol 12 (1) ◽  
Author(s):  
Steven A Abrams ◽  
Keli M Hawthorne ◽  
Stefanie P Rogers ◽  
Penni D Hicks ◽  
Thomas O Carpenter

2009 ◽  
Vol 23 (S1) ◽  
Author(s):  
R E Litov ◽  
S Groh‐Wargo ◽  
B A Brabec ◽  
E E Ziegler ◽  
S A Abrams ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document